Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

Table 5 Cost differences between chemotherapy-based and hormone therapy-based therapy options based on hormone therapy sensitivity^a

		Total Cohort Analysis	Subgroup analysis
Patient group description		All patients (n = 355)	HT-refractory^b in 1st line (n = 107)	HT-eligible^c in 2nd line (n = 248)
Total cost difference (over 3 lines of therapy)^d	HT instead of CTx in 1st line	€14 362	€7300	NA
Total cost difference (over 3 lines of therapy)^d	HT instead of CTx in 2nd line	€10 368	NA	€10 300
Cost difference (for 1 line of therapy)^d	1st line HT vs 2nd line CTx	€9879 (~€1900/mo)	€7550 (~€1650/mo)	NA
	1st line HT vs 1st line CTx	€15 167 (~€2500/mo)	€13 850 (~€2350/mo)	NA
	2nd line HT vs 2nd line CTx	€8201 (~€1700/mo)	NA	€8550 (~€1700/mo)

Abbreviations: ABC advanced breast cancer, CTx chemotherapy, HT hormone therapy, mo month, NA not applicable
^aNumbers in the table reflect cost savings with HT versus CTx
^bHormone refractory indicated recurrence within 1 year of adjuvant HT
^cHormone eligible indicates de novo (no adjuvant therapy) or recurrent disease ≥1 year following adjuvant HT
^dCosts analysis was based on unit cost assumptions for each country, which were then averaged

ISSN: 1471-2407